Knadler MP - Search Results

1

QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.

Zhang L, Chappell J, Gonzales CR, Small D, Knadler MP, Callaghan JT, Francis JL, Desaiah D, Leibowitz M, Ereshefsky L, Hoelscher D, Leese PT, Derby M. Zhang L, et al. Among authors: knadler mp. J Cardiovasc Pharmacol. 2007 Mar;49(3):146-53. doi: 10.1097/FJC.0b013e318030aff7. J Cardiovasc Pharmacol. 2007. PMID: 17414226 Clinical Trial.

2

Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects.

Chan C, Yeo KP, Pan AX, Lim M, Knadler MP, Small DS. Chan C, et al. Among authors: knadler mp. Br J Clin Pharmacol. 2007 Mar;63(3):310-4. doi: 10.1111/j.1365-2125.2006.02770.x. Epub 2006 Sep 12. Br J Clin Pharmacol. 2007. PMID: 17380590 Free PMC article. Clinical Trial.

3

Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects.

Chappell J, He J, Knadler MP, Mitchell M, Lee D, Lobo E. Chappell J, et al. Among authors: knadler mp. J Clin Pharmacol. 2009 Dec;49(12):1456-66. doi: 10.1177/0091270009344335. Epub 2009 Sep 30. J Clin Pharmacol. 2009. PMID: 19793910 Clinical Trial.

4

Effect of duloxetine on tolterodine pharmacokinetics in healthy volunteers.

Hua TC, Pan A, Chan C, Poo YK, Skinner MH, Knadler MP, Gonzales CR, Wise SD. Hua TC, et al. Among authors: knadler mp. Br J Clin Pharmacol. 2004 May;57(5):652-6. doi: 10.1111/j.1365-2125.2004.02068.x. Br J Clin Pharmacol. 2004. PMID: 15089819 Free PMC article. Clinical Trial.

5

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.

Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD. Skinner MH, et al. Among authors: knadler mp. Clin Pharmacol Ther. 2003 Mar;73(3):170-7. doi: 10.1067/mcp.2003.28. Clin Pharmacol Ther. 2003. PMID: 12621382

6

Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women.

Lobo ED, Loghin C, Knadler MP, Quinlan T, Zhang L, Chappell J, Lucas R, Bergstrom RF. Lobo ED, et al. Among authors: knadler mp. Clin Pharmacokinet. 2008;47(2):103-9. doi: 10.2165/00003088-200847020-00003. Clin Pharmacokinet. 2008. PMID: 18193916 Clinical Trial.

7

In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine.

Lobo ED, Bergstrom RF, Reddy S, Quinlan T, Chappell J, Hong Q, Ring B, Knadler MP. Lobo ED, et al. Among authors: knadler mp. Clin Pharmacokinet. 2008;47(3):191-202. doi: 10.2165/00003088-200847030-00005. Clin Pharmacokinet. 2008. PMID: 18307373 Clinical Trial.

8

Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials.

Lobo ED, Heathman M, Kuan HY, Reddy S, O'Brien L, Gonzales C, Skinner M, Knadler MP. Lobo ED, et al. Among authors: knadler mp. Clin Pharmacokinet. 2010 May;49(5):311-21. doi: 10.2165/11319330-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20384393 Clinical Trial.

9

Duloxetine: clinical pharmacokinetics and drug interactions.

Knadler MP, Lobo E, Chappell J, Bergstrom R. Knadler MP, et al. Clin Pharmacokinet. 2011 May;50(5):281-94. doi: 10.2165/11539240-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21366359 Review.

10

Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly.

Callaghan JT, Rubin A, Knadler MP, Bergstrom RF. Callaghan JT, et al. Among authors: knadler mp. J Clin Pharmacol. 1987 Aug;27(8):618-24. doi: 10.1002/j.1552-4604.1987.tb03075.x. J Clin Pharmacol. 1987. PMID: 2888796

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters